BTIG Reaffirms Buy Rating for Oruka Therapeutics and Increases Price Target to $63
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Source: Benzinga
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Users can access the most accurate stock market intelligence to improve their trading outcomes.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ORKA
Wall Street analysts forecast ORKA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORKA is 51.67 USD with a low forecast of 40.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.160
Low
40.00
Averages
51.67
High
75.00
Current: 35.160
Low
40.00
Averages
51.67
High
75.00
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Five Below Options Volume Hits 7,969 Contracts, 71.5% of Daily Average
- Active Options Trading: Five Below Inc's options volume reached 7,969 contracts today, equivalent to approximately 796,900 shares, indicating significant market activity and representing 71.5% of its average daily trading volume of 1.1 million shares over the past month.
- High Demand Options: Notably, the $220 strike call option expiring on January 16, 2026, saw 1,886 contracts traded today, representing about 188,600 shares, reflecting strong market interest at this price level.
- PureCycle Trading Activity: Concurrently, PureCycle Technologies Inc experienced options trading volume of 27,453 contracts, equivalent to approximately 2.7 million shares, which is about 71.3% of its average daily trading volume of 3.9 million shares over the past month, indicating investor attention on this stock as well.
- Put Option Activity: Within PureCycle, the $11 strike put option expiring on March 20, 2026, saw 3,979 contracts traded today, representing approximately 397,900 shares, reflecting a cautious market sentiment regarding the stock's future performance.
Continue Reading
Oruka to Present Novel Biologics at 44th Annual J.P. Morgan Healthcare Conference
- Conference Presentation: Oruka Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, which is expected to attract attention from investors and industry experts, thereby enhancing the company's visibility in the biologics sector.
- Innovative Treatment: Oruka is developing novel biologics targeting chronic skin diseases like plaque psoriasis, aiming for high rates of complete disease clearance with dosing as infrequently as once or twice a year, significantly improving patients' quality of life.
- Technological Advantage: The biologics are engineered by Paragon Therapeutics to target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases, showcasing the company's R&D strength and market potential in biotechnology.
- Investor Relations: Oruka will provide a webcast and replay of the presentation on its investor events website, enhancing engagement with investors and increasing transparency to attract more attention to its innovative products.
Continue Reading